Certara stock (US1567671046): Q1 revenue up 1% but services decline sparks investigation

Certara released Q1 2026 results on May 11, showing 1% revenue growth to $106.9 million amid an EPS miss and 4% services revenue drop, prompting a securities fraud probe by Kirby McInerney LLP.

Certara, a leader in biosimulation software for drug development, reported its first quarter 2026 financial results on May 11, 2026. Total revenue rose 1% year-over-year to $106.9 million, but services revenue fell 4% to $57.2 million, according to the earnings disclosure as of 05/11/2026. The EPS miss led to a stock drop, while Kirby McInerney LLP launched an investigation into potential securities fraud.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Certara, Inc.
• Sector/industry: Biosimulation software and services
• Headquarters/country: United States
• Core markets: Pharmaceutical and biotech drug development
• Key revenue drivers: Software licenses, services, biosimulation tools
• Home exchange/listing venue: Nasdaq (CERT)
• Trading currency: USD

Certara: core business model

Certara operates as a provider of advanced biosimulation software, technology, and services to pharmaceutical, biotechnology, and medical device companies. The company's platform integrates modeling, simulation, and regulatory science to accelerate drug discovery and development. This model helps clients optimize clinical trials and gain regulatory approvals more efficiently, according to company filings on ir.certara.com as of 05/14/2026.

Key to Certara's offerings is its suite of software tools like Simcyp for physiologically based pharmacokinetic modeling and Phoenix for data analysis. These tools are used across drug development phases, from preclinical research to regulatory submissions. The company generates recurring revenue through software licenses and maintenance, supplemented by professional services.

Main revenue and product drivers for Certara

Software revenue forms the backbone of Certara's business, driven by subscriptions and licenses for its biosimulation platforms. In Q1 2026, while total revenue reached $106.9 million with 1% growth, the services segment underperformed with a 4% decline to $57.2 million, as reported in the earnings call transcript as of 05/11/2026. This mix highlights reliance on both SaaS-like software and project-based services.

Biosimulation tools remain a top driver, enabling clients to predict drug behavior in humans without extensive trials. Partnerships with major pharma firms bolster adoption, contributing to stable revenue streams amid industry demand for cost-effective R&D.

Industry trends and competitive position

The biosimulation market is expanding due to rising drug development costs and regulatory pressures for efficient trials. Certara holds a strong position with its end-to-end platform, competing with firms like Simulations Plus and Rosa & Co. Its focus on AI-enhanced modeling aligns with sector shifts toward digital twins in pharma R&D.

Why Certara matters for US investors

Listed on Nasdaq under CERT, Certara offers US investors exposure to the innovative intersection of biotech and software. With the US pharma sector driving global drug innovation, Certara's tools support key players like Pfizer and Moderna, tying its growth to American healthcare advancements and FDA approvals.

Conclusion

Certara's Q1 2026 results showed modest revenue growth overshadowed by a services decline and EPS miss, triggering a legal investigation and analyst price target adjustments. Insider equity grants signal confidence in long-term incentives, while the core biosimulation business remains pivotal in drug development. Investors track upcoming quarters for services recovery and market execution.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.